Connect with us

Hi, what are you looking for?

Investing

Journey Medical Up 21% on Rosacea-Drug Data

Published

By Josh Beckerman

Shares of Journey Medical were up 21%, to $2.03, as it reported favorable topline Phase 1 study data for a papulopustular rosacea treatment it is developing in collaboration with Dr. Reddy’s Laboratories.

Journey Medical said it is “very pleased” with the results for DFD-29, which indicate that it can be safely used for up…

Read the full article here

In this article:
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Videos

How Does The Black Box Survive Airplane Crashes

Watch full video on YouTube

6 days ago

Videos

How Levi’s, Gap And American Eagle Are Winning Back U.S. Shoppers

Watch full video on YouTube

5 days ago

News

Disc Medicine, Inc. (IRON) Discusses ASH Conference Data Updates and Portfolio Progress Including Anemia and Iron Restriction Programs Transcript

Follow Play Earnings CallPlay Earnings Call Disc Medicine, Inc. (IRON) Discusses ASH Conference Data Updates and Portfolio Progress Including Anemia and Iron Restriction Programs...

23 hours ago

Videos

Key takeaways from AMD’s analyst day, plus economic damage of the govt shutdown

Watch full video on YouTube

6 days ago